Bio-Path (BPTH) Competitors $0.15 +0.01 (+11.03%) As of 05/1/2025 03:11 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BPTH vs. ATNF, KTTA, SONN, DRMA, AEON, CMND, ALZN, LIXT, KLTO, and OGENShould you be buying Bio-Path stock or one of its competitors? The main competitors of Bio-Path include 180 Life Sciences (ATNF), Pasithea Therapeutics (KTTA), Sonnet BioTherapeutics (SONN), Dermata Therapeutics (DRMA), AEON Biopharma (AEON), Clearmind Medicine (CMND), Alzamend Neuro (ALZN), Lixte Biotechnology (LIXT), Klotho Neurosciences (KLTO), and Oragenics (OGEN). These companies are all part of the "pharmaceutical products" industry. Bio-Path vs. 180 Life Sciences Pasithea Therapeutics Sonnet BioTherapeutics Dermata Therapeutics AEON Biopharma Clearmind Medicine Alzamend Neuro Lixte Biotechnology Klotho Neurosciences Oragenics 180 Life Sciences (NASDAQ:ATNF) and Bio-Path (NASDAQ:BPTH) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, community ranking, dividends and media sentiment. Does the MarketBeat Community favor ATNF or BPTH? Bio-Path received 280 more outperform votes than 180 Life Sciences when rated by MarketBeat users. Likewise, 52.61% of users gave Bio-Path an outperform vote while only 18.18% of users gave 180 Life Sciences an outperform vote. CompanyUnderperformOutperform180 Life SciencesOutperform Votes218.18%Underperform Votes981.82% Bio-PathOutperform Votes28252.61% Underperform Votes25447.39% Which has higher earnings & valuation, ATNF or BPTH? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/A-$19.93MN/AN/ABio-PathN/AN/A-$16.08MN/AN/A Which has more volatility and risk, ATNF or BPTH? 180 Life Sciences has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500. Comparatively, Bio-Path has a beta of -0.14, indicating that its stock price is 114% less volatile than the S&P 500. Do analysts prefer ATNF or BPTH? Bio-Path has a consensus price target of $20.00, suggesting a potential upside of 13,233.33%. Given Bio-Path's stronger consensus rating and higher possible upside, analysts plainly believe Bio-Path is more favorable than 180 Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 180 Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Bio-Path 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ATNF or BPTH more profitable? 180 Life Sciences' return on equity of -558.93% beat Bio-Path's return on equity.Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A -558.93% -54.10% Bio-Path N/A -2,842.40%-337.48% Do insiders & institutionals believe in ATNF or BPTH? 4.1% of 180 Life Sciences shares are held by institutional investors. Comparatively, 5.7% of Bio-Path shares are held by institutional investors. 0.2% of 180 Life Sciences shares are held by insiders. Comparatively, 0.7% of Bio-Path shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media favor ATNF or BPTH? In the previous week, 180 Life Sciences and 180 Life Sciences both had 2 articles in the media. 180 Life Sciences' average media sentiment score of 0.14 beat Bio-Path's score of 0.00 indicating that 180 Life Sciences is being referred to more favorably in the media. Company Overall Sentiment 180 Life Sciences Neutral Bio-Path Neutral SummaryBio-Path beats 180 Life Sciences on 8 of the 12 factors compared between the two stocks. Get Bio-Path News Delivered to You Automatically Sign up to receive the latest news and ratings for BPTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BPTH vs. The Competition Export to ExcelMetricBio-PathPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.25M$6.85B$5.54B$7.93BDividend YieldN/A2.95%5.09%4.23%P/E RatioN/A7.3222.6018.55Price / SalesN/A241.43400.01103.29Price / CashN/A65.8538.1834.62Price / Book0.216.486.774.25Net Income-$16.08M$143.41M$3.22B$248.18M7 Day Performance3.45%1.91%1.10%0.91%1 Month Performance-11.87%4.28%2.48%2.58%1 Year Performance-94.36%-3.87%15.71%4.02% Bio-Path Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BPTHBio-Path1.5334 of 5 stars$0.15+11.0%$20.00+13,233.3%-94.6%$1.25MN/A0.0010Gap UpATNF180 Life SciencesN/A$0.89+0.6%N/A-33.2%$4.59MN/A0.007News CoverageGap UpKTTAPasithea Therapeutics0.5139 of 5 stars$1.69-2.3%N/A-78.0%$4.57MN/A-0.133Gap DownSONNSonnet BioTherapeutics1.3878 of 5 stars$1.49+8.8%$20.00+1,242.3%-24.7%$4.57M$1M0.0010Short Interest ↑Gap DownDRMADermata Therapeutics2.9229 of 5 stars$0.75+1.8%$6.00+697.9%-83.5%$4.54MN/A-0.058Upcoming EarningsPositive NewsAEONAEON Biopharma1.7149 of 5 stars$0.42-2.4%$360.00+85,614.3%-99.8%$4.42MN/A2.335Gap UpCMNDClearmind Medicine1.0831 of 5 stars$1.03+1.0%N/A-13.6%$4.39MN/A-0.55N/AShort Interest ↓Gap UpALZNAlzamend Neuro3.495 of 5 stars$0.66-2.6%$20.00+2,921.1%-90.7%$4.38MN/A0.004Short Interest ↓Negative NewsGap UpLIXTLixte Biotechnology1.0925 of 5 stars$1.39+8.2%N/A-56.3%$4.36MN/A-0.804Upcoming EarningsPositive NewsGap UpKLTOKlotho NeurosciencesN/A$0.18+5.0%N/AN/A$4.35MN/A0.00N/AGap UpOGENOragenicsN/A$0.19-2.7%N/A-80.7%$4.12M$40,000.00-0.035Analyst ForecastGap Up Related Companies and Tools Related Companies ATNF Alternatives KTTA Alternatives SONN Alternatives DRMA Alternatives AEON Alternatives CMND Alternatives ALZN Alternatives LIXT Alternatives KLTO Alternatives OGEN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BPTH) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bio-Path Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bio-Path With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BPTH Stock Free BPTH Stock Alerts